Biomarker positive and negative subjects in the ADNI cohort: Clinical characterization

Current Alzheimer Research

Volumn 9, Issue 10, 2012, Pages 1135-1141

  Kennedy, Richard E ^a   Schneider, Lon S ^b   Cutter, Gary R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

ADNI; Alzheimer's disease; Amyloid; Biomarker; Clinical trials; Confounding; Prediction

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE; ALZHEIMER DISEASE NEUROIMAGING INITIATIVE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FUNCTIONAL ACTIVITIES QUESTIONNAIRE; FUNCTIONAL NEUROIMAGING; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUESTIONNAIRE; RATING SCALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; SPINAL PUNCTURE; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 84874849813     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512804142976     Document Type: Article

References (40)

1. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, et al. The Alzheimer's Disease Neuroimaging Initiative. Neuroimaging Clin N Am 15: 869-77 (2005).
2. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol 65: 403-13 (2009).
3. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734-46 (2007).
4. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-28 (2010).
5. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6: 131-44 (2010).
6. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization. Neurology 74: 201-9 (2010).
7. A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease http://clinicaltrials.gov/ct2/show/NCT00890890?term=Alzheimer&lead=Bristol&rank=2, accessed April 15, 2010.
8. Schneider LS, Kennedy RE, Cutter GR. Requiring an amyloid- 1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 6: 367-377 (2010).
9. Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 1: 55-66 (2005).
10. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379-88 (2005).
11. Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, et al. Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial. Neurology 72: 1555-1561 (2009).
12. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43: 2412-4 (1993).
13. Wechsler DA. Wechsler Memory Scale-Revised. New York: Psychological Corporation (1987).
14. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(2): S13-21 (1997).
15. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975).
16. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 37: 323-329 (1982).
17. Schmidt M. Rey Auditory and Verbal Learning Test: A handbook. Los Angeles, CA: Western Psychological Services (1996).
18. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer Dement 7: 270-279 (2011).
19. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 9: 1118-1127 (2011).
20. 181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51: 336-345 (2005).
21. Vanderstichele H, De Meyer G, Shapiro F, Engelborghs B, De Deyn PP, Shaw LM, et al. Alzheimer's disease biomarkers: from concept to clinical utility. In (Eds: Galimberti D and Scarpini E). BioMarkers for early diagnosis of Alzheimer's disease. Haupauge, NY:Nova Science Publishers pp 81-122 (2008).
22. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121:597-609 (2011).
23. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75: 800-803 (1988).
24. SAS Institute Inc. SAS version 9.2. Cary, NC: SAS Institute Inc. (2004).
25. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing (2009). URL http://www.R-project.org.
26. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-9 (2007).
27. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-93 (2009).
28. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5: 228-34 (2006).
29. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8: 619-27 (2009).
30. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67: 949-56 (2010).
31. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, et al. Mild cognitive impairment. Lancet 367: 1262-70 (2006).
32. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 10: 6759-6763 (2004).
33. Mungas D, Harvey D, Reed BR, Jagust WJ, DeCarli C, Beckett L, et al. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology 65: 565-571 (2005).
34. Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, et al. Independent contribution of temporal -amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 134:798-807 (2011).
35. Chételat G, Villemagne VL, Pike KE, Ellis KA, Ames D, Masters CL, et al. Relationship between memory performance and - amyloid deposition at different stages of Alzheimer's disease. Neuro-degenerative Diseases 10:141-144 (2012).
36. Schmand B, Huizenga HM, Van Gool WA. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med 29: 1-11 (2009).
37. Davidson JE, Irizarry MC, Bray BC, Wetten S, Galwey N, Gibson R, et al. An exploration of cognitive subgroups in Alzheimer's disease. J Int Neuropsychol Soc 16: 233-243 (2010).
38. Doody RS, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression of Alzheimer's disease. Alzheimers Res Ther 2: 2 (2010).
39. Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, De-Kosky ST, et al. Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr 22: 281-290 (2010).
40. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-8 (1999).